Avanos Medical, Inc.

Good morning, ladies and gentlemen, and welcome to the Avanos Medical Avanos First Quarter 2025 Earnings Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If, at any time during this call, you require immediate assistance, please press star zero for the operator. This call is being recorded on Tuesday, May 6, 2025. I would now like to turn the conference over to Scott Gullivan. Please go ahead.

Good morning, everyone, and thanks for joining us. It's my pleasure to welcome you to Avanos 2025 First Quarter Earnings Conference Call. I'm pleased to start today's call by welcoming Dave Pacitti as the new Chief Executive Officer of Avanos. Dave's extensive commercial expertise and industry knowledge have consistently driven growth and transformation throughout his career. We're excited to have Dave on board as we believe his leadership will be instrumental in advancing our strategic priorities and unlocking new opportunities for the company. I'm also pleased to introduce Jason Pickett, who was recently appointed Interim CFO and Treasurer. With more than 30 years in corporate finance and accounting, including over a decade here at Avanos, most recently as Vice President, Finance, and Treasurer, Jason's experience and deep institutional knowledge make him well-suited to serve in this interim capacity. During today's call, Dave will provide a high-level overview of our first quarter results and share his initial thoughts and observations on the business environment and our product portfolio. Jason will then share additional details on these topics, as well as an update on our transformation initiatives and our 2025 planning assumptions including the impact of tariffs. We will finish the call with Q&A. A presentation for today's call is available on the Investors section of our website, avanos.com. As a reminder, our comments today contain forward-looking statements related to the company, our expected performance, current economic conditions, including risks related to ongoing tariff negotiations, and our industry. No assurance can be given as to future financial results. Actual results could differ materially from those in the forward-looking statements. For more information about forward-looking statements and the risk factors that could influence future results, please see today's press release and risk factors described in our filings with the SEC. Additionally, we'll be referring to adjusted results and outlook. The press release has information on these adjustments and reconciliations to comparable GAAP financial measures. Now, I'll turn the call over to Dave.

Thanks, Scott. Good morning, everyone, and thank you for joining us to review our operational and financial results for the first quarter 2025. We delivered a strong first quarter anchored by continued healthy performance of our specialty nutrition system segment, along with notable progress in our pain management and recovery segment. Before Jason shares details on our financial results, I'd like to take a few minutes to share initial observations after my first couple of weeks at the company. First and foremost, the transformation efforts made around the portfolio, organization structure, and cost management have laid a strong foundation for enhancing our growth profile, particularly as we look to deploy capital for M&A and partnerships. Additionally, I'm very encouraged by the strong energy and strategic focus I'm seeing across the company. This focus creates opportunities to enhance execution consistency, explore new go-to-market approaches, and strengthen our margin profile. As I gain deeper insight into the business over the coming quarters, I look forward to sharing more fully developed perspectives. Now, let me turn the call over to Jason to review our financial results for the quarter.